Repositioning Candidate Details
| Candidate ID: | R1391 |
| Source ID: | DB11691 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Naldemedine |
| Synonyms: | Naldemedine |
| Molecular Formula: | C32H34N4O6 |
| SMILES: | [H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]5(O)CC(C(=O)NC(C)(C)C1=NC(=NO1)C1=CC=CC=C1)=C2O)=CC=C3O |
| Structure: |
|
| DrugBank Description: | Naldemedine is an opioid receptor antagonist . It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. |
| CAS Number: | 916072-89-4 |
| Molecular Weight: | 570.646 |
| DrugBank Indication: | For the treatment of opioid-induced constipation . |
| DrugBank Pharmacology: | Naldemedine is an opioid receptor antagonist with restricted movement across the blood brain barrier . This allows it to antagonize the periperal effects of opioid drugs such as constipation without interfering with the effects on the central nervous system. |
| DrugBank MoA: | Naldemedine binds to and antagonizes mu-, delta-, and kappa-opioid receptors . The binding of opioid agonists to peripheral mu-opioid receptors slows the transit of feces through the intestine resulting in constipation. By antagonizing mu-opioid receptors, naldemedine inhibits this effect. |
| Targets: | Mu-type opioid receptor antagonist; Delta-type opioid receptor antagonist; Kappa-type opioid receptor antagonist |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|